MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Walter, R F H; Mairinger, F D; Ting, S; Vollbrecht, C; Mairinger, T; Theegarten, D; Christoph, D C; Schmid, K W; Wohlschlaeger, J

Walter, R F H; Mairinger, F D; Ting, S; Vollbrecht, C; Mairinger, T; Theegarten, D; Christoph, D C; Schmid, K W; Wohlschlaeger, J.

Afiliação

Walter RF; 1] Ruhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, Tüschener Weg 40, Essen D-45239, Germany [2] Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Mairinger FD; Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ting S; Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Vollbrecht C; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Mairinger T; Department of Pathology, Helios Klinikum Emil von Behring, Berlin, Germany.
Theegarten D; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Christoph DC; 1] Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany [2] Department of Medicine, Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA.
Schmid KW; Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Wohlschlaeger J; Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Br J Cancer ; 112(5): 883-90, 2015 Mar 03.

Article em En | MEDLINE | ID: mdl-25668009

Assuntos

Inibidor p16 de Quinase Dependente de Ciclina/genética; Mesotelioma/genética; Mesotelioma/mortalidade; Neoplasias Pleurais/genética; Neoplasias Pleurais/mortalidade; Proteínas Proto-Oncogênicas c-mdm2/genética; Proteínas Proto-Oncogênicas c-mdm2/metabolismo; Idoso; Idoso de 80 Anos ou mais; Antineoplásicos/uso terapêutico; Feminino; Regulação Neoplásica da Expressão Gênica; Glutamatos/uso terapêutico; Guanina/análogos & derivados; Guanina/uso terapêutico; Humanos; Masculino; Mesotelioma/tratamento farmacológico; Mesotelioma/metabolismo; Pessoa de Meia-Idade; Compostos Organoplatínicos/uso terapêutico; Pemetrexede; Neoplasias Pleurais/tratamento farmacológico; Neoplasias Pleurais/metabolismo; Análise de Sobrevida; Proteína Supressora de Tumor p53/metabolismo

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Inibidor p16 de Quinase Dependente de Ciclina / Proteínas Proto-Oncogênicas c-mdm2 / Mesotelioma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google